Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Status:
Recruiting
Trial end date:
2022-09-16
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out if a study treatment called Inclisiran can be given
in regional primary care setting (i.e. at a GP surgery in the NHS) in the UK, and to
understand how this health care service may be set-up by the NHS.
Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad"
cholesterol (LDL-cholesterol) in the blood. Inclisiran works in a way that makes the liver
produce less of a substance called 'PCSK9'. PCSK9 reduces the ability of the liver to remove
LDL-cholesterol from the blood. By lowering the production of PCSK9, Inclisiran leads to more
LDL-cholesterol being removed by the liver from the blood, thereby reducing LDL-cholesterol
overall.
About 900 patients will participate in this study, at about 20 GP surgeries across the
Greater Manchester area within the UK.